Smart Immune

Executive Summary

Smart Immune is a French biotechnology company pioneering a novel T-cell progenitor therapy platform called ProTcell. Founded in 2017 and headquartered in Paris, the company aims to accelerate and improve immune reconstitution in patients with cancer and infectious diseases by generating a fully functional, diverse, and patient-specific adaptive immune system from transplanted hematopoietic stem cells. The platform addresses a critical unmet need in immunocompromised patients, such as those undergoing stem cell transplantation or suffering from severe infections. With a focus on cell and gene therapy, Smart Immune's approach could potentially reduce the time to immune recovery, lower infection risk, and improve overall outcomes. The company is still in the preclinical stage, with no disclosed funding rounds or clinical trials, indicating an early developmental phase. However, the technology holds promise for transforming the treatment landscape for immune deficiencies and hematologic malignancies. Key upcoming milestones include regulatory filings, preclinical data releases, and potential partnership announcements that could validate the platform and pave the way for clinical trials.

Upcoming Catalysts (preview)

• Q2 2026IND/CTA Filing for ProTcell in Hematologic Malignancies60% success
• Q4 2026Preclinical Proof-of-Concept Data in Infectious Disease Model70% success
• Q1 2027Strategic Partnership or Licensing Deal with Major Pharma50% success